Vitolo, U., Norasetthada, L., Jo, J., Shen, B., Flink, D., Zhu, M., Chandrasekharan, S., Chen, J., Brouwer-Visser, J., Chaudhry, A., Mohamed, H., Bobillo-Varela, S., Thieblemont, C. (2025). Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study. Blood. https://doi.org/10.1182/blood-2025-5381